Open label oncolytic virus treatment of refractory cancer under the EU hospital exemption, article 28 of Regulation 1394/2007/EC.

Trial Profile

Open label oncolytic virus treatment of refractory cancer under the EU hospital exemption, article 28 of Regulation 1394/2007/EC.

Suspended
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Aug 2013

At a glance

  • Drugs ONCOS 102 (Primary) ; Antineoplastics; Oncolytic viruses
  • Indications Solid tumours
  • Focus Biomarker; Therapeutic Use
  • Acronyms ATAP
  • Most Recent Events

    • 02 Aug 2013 Status changed to suspended. The programme is on hold and not recruiting patients, due to the initiation of clinical trials.
    • 07 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top